ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Inflammation Disrupts Memory - What Can You Do to Protect Your Brain?

All About Ginkgo Biloba: Benefits of This Timeless Herbal Supplement

Yarrow Oil: Here's Why It Deserves a Place in Your First-Aid Kit

Artificial sweeteners linked to risk of weight gain, heart disease and other health issues

Trial Finds Reduction in Depressive Symptoms Following Magnesium Supplementation

Vitamin D supplement use associated with lower risk of breast cancer

Carnitine deficiency suggested as contributor to autism

Hop Oil: A Safe Sleep Aide

White Camphor Oil: The Purest Camphor Oil

Lutein — An Important Nutrient for Eye and Brain Health

 
Print Page
Email Article

UAMS Reports Bone Loss From Oral Diabetes Drug

  [ 30 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 9, 2003


LITTLE ROCK, Ark., Oct. 8 /PRNewswire/ -- Scientists at the University of Arkansas for Medical Sciences (UAMS) report in the journal Endocrinology that a widely used oral drug for type 2 diabetes may pose a significant risk of bone loss.

The researchers report that in a laboratory study the anti-diabetic compound rosiglitazone (known as Avandia), caused a significant decrease in total body bone mineral density, suggesting that Avandia therapy may pose a significant risk of adverse skeletal effects in humans.

"Avandia is an FDA-approved and clinically successful treatment for type 2 diabetes. Our findings suggest that doctors should watch the skeletons of patients who use this drug, especially older patients, because their patients may be at increased risk of bone loss over time," said lead researcher Beata Lecka-Czernik, Ph.D., a molecular and cell biologist.

An estimated 16 million Americans have type 2 diabetes, which results from insulin resistance, a condition in which the body does not properly use insulin, along with relative insulin deficiency. The disease typically develops in people over the age of 40. Rosiglitazone, a very effective anti-diabetic agent that reduces insulin resistance, has had federal approval since 1999.

The National Institute on Aging funded the research at UAMS with a five-year, $925,000 grant. Physiologists and endocrinologists Larry J. Suva, Ph.D., and Dana Gaddy, Ph.D., are co-investigators. Lecka-Czernik is a member of the Donald W. Reynolds Department of Geriatrics and Suva and Gaddy are members of the faculty of the Departments of Orthopaedic Surgery and Physiology and Biophysics, all in the UAMS College of Medicine. All three researchers are members of the Arkansas Cancer Research Center at UAMS. S. O. Rzonca and D. C. Montague, research assistants who conducted the experiment and technical analyses, are co-authors of the article in Endocrinology.

The UAMS scientists used micro-computed tomography to analyze the bones of healthy mice that received doses of rosiglitazone over seven weeks. The doses that mice received were the same doses mice received in earlier studies that demonstrated the compound's effectiveness for type 2 diabetes. The researchers next plan to test the effects of the drug on mice and rats with diabetes. Lecka-Czernik also has a grant for the follow-up study of $300,000
for three years from the American Diabetes Association.

A gift of $288,000 from the Roy and Christine Sturgis Charitable Trust in 2002 enabled UAMS to purchase the sophisticated bone analysis equipment used in the study.

The journal Endocrinology is published by The Endocrine Society. UAMS is the leading biomedical research institution in Arkansas and the home of the Donald W. Reynolds Center on Aging as well as the Donald W. Reynolds Department of Geriatrics.

SOURCE: University of Arkansas for Medical Sciences
Web Site: http://www.uams.edu



Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil FibroSleep™ Optimized Curcumin Longvida®


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You
The Fast-Acting Solution for Healthy Digestive Function The Fast-Acting Solution for Healthy Digestive Function
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed
Eating Fat is Good... Maybe... Could Be... Sometimes Eating Fat is Good... Maybe... Could Be... Sometimes

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map